ProMIS Neurosciences Inc./$PMN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
- Ticker
- $PMN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 11
- Headquarters
- Toronto, Canada
- Website
- www.promisneurosciences.com
PMN Metrics
BasicAdvanced
$34M
-
-$8.45
-0.22
-
Price and volume
Market cap
$34M
Beta
-0.22
52-week high
$27.40
52-week low
$2.78
Average daily volume
283K
Financial strength
Current ratio
7.855
Quick ratio
7.437
Profitability
Management effectiveness
Return on assets (TTM)
-81.06%
Return on equity (TTM)
-172.30%
Valuation
Price to book
0.68
Price to tangible book (TTM)
0.68
Price to free cash flow (TTM)
-0.446
Free cash flow yield (TTM)
-224.10%
Free cash flow per share (TTM)
-8.426
Growth
Earnings per share change (TTM)
34.67%
3-year earnings per share growth (CAGR)
-48.68%
10-year earnings per share growth (CAGR)
-7.87%
What the Analysts think about PMN
Analyst ratings (Buy, Hold, Sell) for ProMIS Neurosciences Inc. stock.
Analyst projections of the future price of ProMIS Neurosciences Inc. stock.
PMN Financial Performance
Revenues and expenses
PMN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.